Clinical Trials Logo

Lung Cancer Stage III clinical trials

View clinical trials related to Lung Cancer Stage III.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06060964 Not yet recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management

Breathe Easier
Start date: October 2, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the preliminary affects of "Breathe Easier," an evidence-based multi-level mindfulness intervention (i.e., progressive web application) for survivors of lung cancer. The key aims of this study are to (1) Evaluate the feasibility (usability, acceptability intervention adherence) of the "Breathe Easier" and (2) assess the impact of the intervention on dyspnea, fatigue, and quality of life among survivors of lung cancer. Participants in the intervention group will use the "Breathe Easier" progressive web application for a period of 8-weeks, while participants in the control group will receive no intervention. Researchers will compare the intervention and control groups to see if there are salient differences in dyspnea, fatigue, and quality of life between the two groups.

NCT ID: NCT05994339 Not yet recruiting - Clinical trials for Lung Cancer Stage III

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Start date: September 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Study Object: Stage III lung cancer with epidermal growth factor receptor (EGFR) sensitive mutation. Study Method: The study subjects will be randomly assigned to the intervention group and the control group. The intervention group will receive radiotherapy combined with erlotinib treatment, while the control group will receive concurrent radiotherapy combined with chemotherapy. The differences in short-term efficacy, long-term efficacy, and incidence of adverse reactions between the two groups will be observed. Observation Indicators: Short-term efficacy indicators: Complete remission (CR) rate, partial remission (PR) rate, and objective response rate (ORR). Long-term efficacy indicators: Overall survival (OS) and progression-free survival (PFS). Adverse reaction indicators: Incidence of lung toxicity, hematological toxicity, and gastrointestinal reactions.

NCT ID: NCT05358691 Not yet recruiting - Clinical trials for Lung Cancer Stage III

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Start date: January 30, 2024
Phase: Phase 1
Study type: Interventional

Primary - Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation) - Evaluate efficacy by progression-free survival (PFS), objective response rate (ORR), and time to death or distant metastasis (TTMD), Duration of response (DOR), Overall survival (OS) with the addition of AN0025 in both the consolidative and concurrent settings Exploratory - Evaluate pharmacokinetics of AN0025 in conjunction with chemoradiation, and then with durvalumab